What is BPC-157? Mechanism of Action & Literature Review

BPC-157 is a synthetic pentadecapeptide (sequence: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) isolated from human gastric juice. The Sikiric group at the University of Zagreb has published the majority of the studies on it. Unlike many other research peptides, BPC-157 shows notable stability in aqueous solution and is not readily degraded by peptidases.

The research data suggest that BPC-157 acts through multiple pathways: (1) activation of the FAK-paxillin pathway driving cell migration, (2) modulation of VEGF expression relevant to angiogenesis, (3) interaction with nitric oxide (NO) signalling, and (4) increased expression of collagen and extracellular matrix proteins. In rodent models it shows notable effects in tendon and muscle injury, GI ulceration and neurological damage.

In preclinical studies, reported ranges are typically presented in mcg/kg for rodent models and vary considerably by experimental design. Translating these into human equivalents is scientifically uncertain, and no approved clinical protocols exist. For educational research context, see the BPC-157 hub, the Peptide Calculator and the peptide reconstitution guide.

One of the distinguishing characteristics of BPC-157 is its resilience in the gastrointestinal environment, which explains the research interest in oral formats. Rodent studies show experimental responses across different formats, but this does not translate into guidance for human use.

Despite the large number of preclinical studies, BPC-157 has not been approved by the FDA or the EMA for any indication. It remains at investigational status. In 2026 the FDA reclassified certain compounded peptides — see FDA Peptide Reclassification 2026 for educational context. In Greece and Cyprus, BPC-157 is not marketed as an approved medicinal product.